Methods
The metabolic stability of rivaroxaban in the presence of human liver
microsomes (HLMs) and recombinant CYPs was systematically evaluated to
estimate the participation of various CYP isoforms. Furthermore, the
catalytic efficiency of CYP isoforms was compared via metabolic kinetic
studies of rivaroxaban with recombinant CYP isoenzymes, as well as via
CYP-specific inhibitory studies. Additionally, docking simulations were
used to illustrate molecular interactions.